NCT03573050View on ClinicalTrials.gov

Rivastigmine BA Trial With Multiple Application of Transdermal Patches, Adaptation and Tapering Phase

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

May 16, 2018

Primary Completion Date

July 5, 2018

Study Completion Date

July 5, 2018

Conditions
Bioequivalence
Interventions
DRUG

RIV-TDS 13.3 mg/24 h

5 consecutive transdermal patch applications, each with a nominal release rate of 13.3 mg/24 hours

DRUG

Exelon® 13.3 mg/24 hours transdermal patch

5 consecutive transdermal patch applications, each with a nominal release rate of 13.3 mg/24 hours

Trial Locations (1)

99084

SocraTec R&D GmbH, Clinical Pharmacology Unit, Erfurt

All Listed Sponsors
collaborator

SocraMetrics GmbH

INDUSTRY

lead

SocraTec R&D GmbH

OTHER

NCT03573050 - Rivastigmine BA Trial With Multiple Application of Transdermal Patches, Adaptation and Tapering Phase | Biotech Hunter | Biotech Hunter